{"id":"NCT02107898","sponsor":"Sanofi","briefTitle":"Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Alirocumab in Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03","primaryCompletion":"2015-01","completion":"2015-09","firstPosted":"2014-04-08","resultsPosted":"2016-01-29","lastUpdate":"2016-10-04"},"enrollment":216,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Placebo (for alirocumab)","otherNames":[]},{"type":"DRUG","name":"Alirocumab","otherNames":["SAR236553","REGN727","Praluent"]},{"type":"DRUG","name":"Lipid-Modifying Therapy (LMT)","otherNames":[]}],"arms":[{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR"},{"label":"Alirocumab 75 mg/Up to 150 mg Q2W","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable daily statin therapy with or without other lipid modifying therapy in comparison with placebo after 24 weeks of treatment in heterozygous familial hypercholesterolemia (HeFH) or high cardiovascular risk participants with hypercholesterolemia.\n\nSecondary Objectives:\n\n* To evaluate the effect of alirocumab in comparison with placebo on LDL-C after 12 weeks of treatment.\n* To evaluate the effect of alirocumab on other lipid parameters.\n* To evaluate the long-term effect of alirocumab in comparison with placebo on LDL-C after 52 weeks of treatment.\n* To evaluate the safety and tolerability of alirocumab.\n* To evaluate the development of anti-alirocumab antibodies.\n* To evaluate the pharmacokinetics of alirocumab.","primaryOutcome":{"measure":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)","timeFrame":"From Baseline to Week 24","effectByArm":[{"arm":"Placebo Q2W","deltaMin":1.6,"sd":1.8},{"arm":"Alirocumab 75 mg/Up to 150 mg Q2W","deltaMin":-62.5,"sd":1.3}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":32,"countries":["Japan"]},"refs":{"pmids":["27452202","33078867"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":72},"commonTop":["Nasopharyngitis","Back pain","Injection site reaction","Diabetes mellitus","Fall"]}}